[1] FERLAY J,SOCRJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.
[2] AUBUCHON M M,BOLT L J,JANSSEN-HEIJNEN M L,et al.Epidemiology,management and survival outcomes of primary cutaneous melanoma:a ten-year overview[J].Acta Chir Belg,2017,117(1):29-35.
[3] GORDON D,HANSSON J,ELORANTA S,et al.Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma[J].Int J Cancer,2017,141(7):1345-1354.
[4] STEVEN T C,ALAN C G,TSAO H.Update on the epidemiology of melanoma[J].Curr Dermatol Rep,2013,2(1):24-34.
[5] 高天文,孙东杰,李春英,等.中国西部两医院1905例皮肤恶性肿瘤回顾分析[J].北京大学学报:医学版,2004,36:469-472.
[6] National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:melanoma(version 1.2018)[DB/OL].http://www.nccn.org.
[7] LENS M B,NATHAN P,BATAILLE V.Excision margins for primary cutaneous melanoma:updated pooled analysis of randomized controlled trials[J].Arch Surg,2007,142(9):885-891.
[8] HUANG J,YU N,LONG X,et al.A systematic review of the keystone design perforator island flap in lower extremity defects[J].Medicine (Baltimore),2017,96(21):e6842.
[9] MOEHRLE M,METZGER S,SCHIPPERT W,et al."Functional" surgery in subungual melanoma[J].Dermatol Surg,2003,29(4):366-374.
[10] PATTERSON R H,HELWIG E B.Subungual malignant melanoma:aclinical-pathologic study[J].Cancer,1980,46(9):2074-2087.
[11] WU L C,GOTTLIEB L J.Glabrous dermal grafting:a 12-year experience with the functional and aesthetic restoration of palmar and plantar skin defects[J].Plast Reconstr Surg,2005,116(6):1679-1685.
[12] CASCINELLI N,MORABITO A,SANTINAMI M,et al.Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk:a randomised trial[J].Lancet,1998,351(9105):793-796.
[13] DONALD L M,JOHN F T,ALISTAIR J C,et al.Finaltrial report of sentinel-node biopsy versus nodal observation in melanoma[J].N Engl J Med,2014,370(7):599-609.
[14] FARIES M B,THOMPSON J F,COCHRAN A J,et al.Completiondissection or observation for sentinel-node metastasis in melanoma[J].N Engl J Med,2017,376(23):2211-2222.
[15] LEE D Y,LAU B J,HUYNH K T,et al.Impact of completion lymph node dissection on patients with positive sentinel lymph node biopsy in melanoma[J].J Am Coll Surg,2016,223(1):9-18.
[16] MADU M F,WOUTERS M W,AKKOOI A C.Sentinel node biopsy in melanoma:current controversies addressed[J].Eur J Surg Oncol,2017,43(3):517-533.
[17] LEITER U,STADLER R,MAUCH C,et al.Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma(DeCOG-SLT):a multicentre,randomised,phase 3 trial[J].Lancet Oncol,2016,17(6):757-767.
[18] AKKOOI A C,WILT J H,VERHOEF C,et al.Clinical relevance of melanoma micrometastases(<0.1 mm) in sentinel nodes:are these nodes to be considered negative?[J].Ann Oncol,2006,17(10):1578-1585.
[19] SCHERI R P,ESSNER R,TURNER R R,et al.Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma[J].Ann Surg Oncol,2007,14(10):2861-2866.
[20] PLOEGF A P,AKKOOI A C,HAYDU L E,et al.The prognostic significance of sentinel node tumour burden in melanoma patients:an international,multicenter study of 1539 sentinel node-positive melanoma patients[J].Eur J Cancer,2014,50(1):111-120.
[21] IVES N J,SUCIU S,EGGERMONT A M M,et al.Adjuvant interferon-α for the treatment of high-risk melanoma:an individual patient data meta-analysis[J].Eur J Cancer,2017,82:171-183.
[22] AGARWALA S S,LEE S J,YIP W,et al.PhaseⅢ randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO,T3a-bNO,T4a-bNO,and T1-4N1a-2a(microscopic) melanoma:atrial of the eastern cooperative oncology group-americancollege of radiology imaging network cancer research group(E1697)[J].J Clin Oncol,2017,35(8):885-892.
[23] MOHR P,HAUSCHILD A,TREFZER U,et al.Intermittenthigh-dose intravenous interferon alfa-2b for adjuvant treatment of stage Ⅲ melanoma:final analysis of a randomized phase Ⅲ dermatologic cooperative oncology group trial[J].J Clin Oncol,2015,33(34):4077-4084.
[24] EIGENTLER T K,GUTZMER R,HAUSCHILD A,et al.Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma:a randomized phase Ⅲ DeCOG trial[J].Ann Oncol,2016,27(8):1625-1632.
[25] McARTHUR G A,CHAPMAN P B,ROBERT C,et al.Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3):extended follow-up of a phase 3,randomised,open-label study[J].Lancet Oncol,2014,15(3):323-332.
[26] WONGCHENKO M J,MCARTHUR G A,DRENO B,et al.Geneexpression profiling in BRAF-mutated melanoma reveals patient subgroups with poor outcomes to vemurafenib that may be overcome by cobimetinib plus vemurafenib[J].Clin Cancer Res,2017,23(17):5238-5245.
[27] ABDEL R O,ELHALAWANI H,AHMED H.Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma,biological rationale and meta-analysis of published data[J].Clin Transl Oncol,2016,18(8):848-858.
[28] COANA Y P,WOLODARSKI M,POSCHKE I,et al.Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma[J].Oncotarget,2017,8(13):21539-21553.
[29] MAIO M,GROB J J,AAMDAL S,et al.Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase Ⅲ trial[J].J Clin Oncol,2015,33(10):1191-1196.
[30] EGGERMONT A M,CHIARION S V,GROB J J,et al.Prolongedsurvival in stage Ⅲ melanoma with ipilimumab adjuvant therapy[J].N Engl J Med,2016,375(19):1845-1855.
[31] RIBAS A,HAMID O,DAUD A,et al.Association of pembrolizumab with tumor response and survival among patients with advanced melanoma[J].JAMA,2016,315(15):1600-1609.
[32] SCHACHTER J,RIBAS A,LONG G V,et al.Pembrolizumab versus ipilimumab for advanced melanoma:final overall survival results of a multicentre,randomised,open-label phase 3 study (KEYNOTE-006)[J].Lancet,2017,390(10105):1853-1862.
[33] HAMID O,PUZANOV I,DUMMER R,et al.Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma[J].Eur J Cancer,2017,86:37-45.
[34] LARKIN J,CHIARION S V,GONZALEZ R,et al.Combinednivolumab and ipilimumab or monotherapyin untreated melanoma[J].N Engl J Med,2015,373(1):23-34.
[35] DAUD A I,WOLCHOK J D,ROBERT C,et al.Programmeddeath-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma[J].J Clin Oncol,2016,34(34):4102-4109.
[36] GOODMAN A M,KATO S,BAZHENOVA L.Tumormutational burden as an independent predictor of response to immunotherapy in diverse cancers[J].Mol Cancer Ther,2017,16(11):2598-2608.
[37] HUA C,BOUSSEMART L,MATEUS C,et al.Association of vitiligowith tumor response in patients with metastatic melanoma treated with pembrolizumab[J].JAMA Dermatol,2016,152(1):45-51.
[38] FAILING J J,YAN Y,PORRATA L F,et al.Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients[J].Melanoma Res,2017,27(6):596-600.
[39] GOPALAKRISHNAN V,SPENCER C N,NEZI L,et al.Gutmicrobiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J].Science,2018,359(6371):97-103.
[40] WANG Y,GAO W,SHI X,et al.Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J].Nature,2017,547(7661):99-103. |
